Judgment of the General Court (Second Chamber) of 15 September 2015

Novartis Europharm Ltd v European Commission

Medicinal products for human use — Marketing authorisation for the generic medicinal product Zoledronic acid Teva Pharma — zoledronic acid — Regulatory data protection period for the reference medicinal products Zometa and Aclasta, containing the active substance zoledronic acid — Directive 2001/83/EC — Regulation (EEC) No 2309/93 and Regulation (EC) No 726/2004 — Global marketing authorisation — Regulatory data protection period

Case T-472/12



Top of the page Documents in the Case
Document Date Name of the parties Subject-matter Curia EUR-Lex Autres Liens
Judgment (OJ)
16/10/2015 Novartis Europharm v Commission
Judgment
ECLI:EU:T:2015:637
15/09/2015 Novartis Europharm v Commission
Judgment (Summary)
ECLI:EU:T:2015:637
15/09/2015 Novartis Europharm v Commission
Application (OJ)
30/11/2012 Novartis Europharm v Commission
Top of the page Legal analysis of the decision or of the case

Reports of Cases

published in the electronic Reports of Cases (Court Reports - general)

Subject-matter

Application for annulment of Commission Decision C (2012) 5894 final of 16 August 2012 granting marketing authorisation to Teva Pharma BV in respect of the medicinal product for human use ‘Zoledronic acid Teva’ in accordance with Article 3 of Regulation (EC) No 726/2004 of the European Parliament and of the Council.

Systematic classification scheme

1.
4 Internal policy of the European Union
  4.11 Approximation of laws
    4.11.14 Pharmaceutical and cosmetic products
      4.11.14.01 Medicinal products for human use
        4.11.14.01.04 Marketing authorisation
          4.11.14.01.04.02 Abridged procedure
4 Internal policy of the European Union
  4.11 Approximation of laws
    4.11.14 Pharmaceutical and cosmetic products
      4.11.14.01 Medicinal products for human use
        4.11.14.01.04 Marketing authorisation
          4.11.14.01.04.02 Abridged procedure
4 Internal policy of the European Union
  4.11 Approximation of laws
    4.11.14 Pharmaceutical and cosmetic products
      4.11.14.01 Medicinal products for human use
        4.11.14.01.04 Marketing authorisation
          4.11.14.01.04.00 General


Citations of case-law or legislation

References in grounds of judgment

Operative part

Information not available

Opinion

Information not available


Dates

Date of the lodging of the application initiating proceedings

  • 30/10/2012

Date of the Opinion

Information not available

Date of the hearing

Information not available

Date of delivery

15/09/2015


References

Publication in the Official Journal

Judgment: OJ C 363 from 03.11.2015, p.26

Application: OJ C 389 from 15.12.2012, p.8

Name of the parties

Novartis Europharm v Commission

Notes on Academic Writings

Information not available



Procedural Analysis Information

Source of the question referred for a preliminary ruling

Information not available

Subject-matter

  • Approximation of laws
  • Public health

Provisions of national law referred to

Information not available

Provisions of international law referred to

Information not available

Procedure and result

  • Actions for annulment : dismissal on substantive grounds

Formation of the Court

deuxième chambre (Tribunal)

Judge-Rapporteur

Martins Ribeiro

Advocate General

Information not available

Language(s) of the Case

  • English

Language(s) of the Opinion

    Information not available